Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 1 (January 1), 2005: pp. 190-196
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.07.172
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lilenbaum, R. C.
Right arrow Articles by Green, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lilenbaum, R. C.
Right arrow Articles by Green, M. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)

Rogerio C. Lilenbaum, James E. Herndon, II, Marcy A. List, Chris Desch, Dorothy M. Watson, Antonius A. Miller, Stephen L. Graziano, Michael C. Perry, Wayne Saville, Philippe Chahinian, Jane C. Weeks, Jimmie C. Holland, Mark R. Green

From the Mount Sinai Comprehensive Cancer Center, Miami Beach, FL; The Cancer and Leukemia Group B Statistical Center, Durham, NC; University of Chicago Cancer Research Center, Chicago, IL; Virginia Commonwealth University, Massey Cancer Center, Richmond, VA; Wake Forest University School of Medicine, Winston-Salem, NC; SUNY Upstate Medical University, Syracuse NY; University of Missouri/Ellis Fischel Cancer Center, Columbia, MO; University of California at San Diego, San Diego, CA; Mount Sinai School of Medicine and Memorial Sloan Kettering Cancer Center, New York, NY; The Dana Farber Cancer Institute, Boston, MA; Medical University of South Carolina, Charleston, SC

Address reprint requests to Rogerio C. Lilenbaum, MD, FACP, The Mount Sinai Comprehensive Cancer Center, 4306 Alton Rd, Miami Beach, FL 33140; e-mail: Rlilenba{at}salick.com

PURPOSE: We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non–small-cell lung cancer.

PATIENTS AND METHODS: A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in combination with carboplatin.

RESULTS: The response rate was 17% in the paclitaxel arm and 30% in the carboplatin-paclitaxel arm (P < .0001). Median failure-free survival was 2.5 months in the paclitaxel arm and 4.6 months in the carboplatin-paclitaxel arm (P = .0002). Median survival times were 6.7 months (95% CI, 5.8 to 7.8) and 8.8 months (95% CI, 8.0 to 9.9), and 1-year survival rates were 32% (95% CI, 27% to 38%), and 37% (95% CI, 32% to 43%), respectively. The overall survival distributions were not statistically different: hazard ratio = 0.91 (95% CI, 0.77 to 1.17; P = .25). Hematological toxicity and nausea were more frequent in the combination arm, but febrile neutropenia and toxic deaths were equally low in both arms. There was no significant survival difference in elderly patients. Performance status 2 patients treated with combination chemotherapy had a better survival rate than those treated with single-agent therapy (P = .019).

CONCLUSION: Combination chemotherapy improves response rate and failure-free survival compared with single-agent therapy, but there was no statistically significant difference in the primary end point of overall survival. The results in elderly patients were similar to younger patients. Performance status 2 patients had a superior outcome when treated with combination chemotherapy.

The research for CALGB 9730 was supported, in part, by grants from the National Cancer Institute (CA31946) to the Cancer and Leukemia Group B (Richard L. Schilsky, Chairman). The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. This research was also partially supported by Bristol-Myers Squibb Company. This research also supported by CA45564, CA33601, CA41287, CA52784, CA03927, CA21060, CA12046, CA11789, CA04457, CA32291, CA77651, CA03927. Additional information appears in the Appendix.

Presented at the plenary Session, American Society of Clinical Oncology Group Meeting, Orlando, FL, May 2002.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Camerini, C. Valsuani, F. Mazzoni, O. Siclari, C. Puccetti, S. Donati, M. Rondini, G. Tartarelli, P. Puccinelli, F. Di Costanzo, et al.
Phase II trial of single-agent oral vinorelbine in elderly (>=70 years) patients with advanced non-small-cell lung cancer and poor performance status
Ann. Onc., November 13, 2009; (2009) mdp525v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, et al.
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer
Ann. Onc., October 15, 2009; (2009) mdp352v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Lilenbaum, X. Wang, L. Gu, J. Kirshner, K. Lerro, and E. Vokes
Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402
J. Clin. Oncol., September 20, 2009; 27(27): 4487 - 4491.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. H. Kim, K. Kubota, K. Goto, K. Yoh, S. Niho, H. Ohmatsu, N. Saijo, and Y. Nishiwaki
A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2
Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 576 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. G. Pallis, C. Gridelli, J. P. van Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. P. Belani, and M. Aapro
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population
Ann. Onc., August 28, 2009; (2009) mdp360v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Goss, D. Ferry, R. Wierzbicki, S. A. Laurie, J. Thompson, B. Biesma, F. R. Hirsch, M. Varella-Garcia, E. Duffield, O. U. Ataman, et al.
Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status
J. Clin. Oncol., May 1, 2009; 27(13): 2253 - 2260.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Grossi, M. Aita, C. Defferrari, F. Rosetti, A. Brianti, G. Fasola, O. Vinante, P. Pronzato, and G. Pappagallo
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
Oncologist, May 1, 2009; 14(5): 497 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
T. E. Stinchcombe and M. A. Socinski
Current Treatments for Advanced Stage Non-Small Cell Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 233 - 241.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. S. Ramalingam and F. R. Khuri
The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer
Oncologist, April 1, 2009; 14(4): 412 - 424.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Langer
The "Lazarus Response" in Treatment-Naive, Poor Performance Status Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation
J. Clin. Oncol., March 20, 2009; 27(9): 1350 - 1354.
[Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
C. Gridelli, P. Maione, and A. Rossi
Chemotherapy and Targeted Therapy for Older Patients with Advanced Non-small Cell Lung Cancer
ASCO Educational Book, January 1, 2009; 2009(1): 283 - 287.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. M. Strauss, J. E. Herndon II, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. H. Harpole, H. H. Gillenwater, D. M. Watson, D. J. Sugarbaker, R. L. Schilsky, et al.
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
J. Clin. Oncol., November 1, 2008; 26(31): 5043 - 5051.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard, and B. Bonan
Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer
Ann. Pharmacother., November 1, 2008; 42(11): 1640 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
NSCLC Meta-Analyses Collaborative Group
Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials
J. Clin. Oncol., October 1, 2008; 26(28): 4617 - 4625.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Herndon II, A. B. Kornblith, J. C. Holland, and E. D. Paskett
Patient Education Level As a Predictor of Survival In Lung Cancer Clinical Trials
J. Clin. Oncol., September 1, 2008; 26(25): 4116 - 4123.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Wheatley-Price, K. Ding, L. Seymour, G. M. Clark, and F. A. Shepherd
Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
J. Clin. Oncol., May 10, 2008; 26(14): 2350 - 2357.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Ramalingam, S. E. Dahlberg, R. Gray, C. J. Langer, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller, and D. H. Johnson
Meaningful Subset Analyses Contribute to Optimal Patient Care
J. Clin. Oncol., April 20, 2008; 26(12): 2064 - 2065.
[Full Text] [PDF]

Home page
 JCOHome page
R. Lilenbaum, R. Axelrod, S. Thomas, A. Dowlati, L. Seigel, D. Albert, K. Witt, and D. Botkin
Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2
J. Clin. Oncol., February 20, 2008; 26(6): 863 - 869.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. A. Rizvi, G. J. Riely, C. G. Azzoli, V. A. Miller, K. K. Ng, J. Fiore, G. Chia, M. Brower, R. Heelan, M. J. Hawkins, et al.
Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 1, 2008; 26(4): 639 - 643.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Ramalingam, S. E. Dahlberg, C. J. Langer, R. Gray, C. P. Belani, J. R. Brahmer, A. B. Sandler, J. H. Schiller, and D. H. Johnson
Outcomes for Elderly, Advanced-Stage Non Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
J. Clin. Oncol., January 1, 2008; 26(1): 60 - 65.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. P. Sculier, J. J. Lafitte, M. Paesmans, J. Lecomte, C. G. Alexopoulos, O. Van Cutsem, V. Giner, A. Efremidis, M. C. Berchier, T. Collon, et al.
Chemotherapy improves low performance status lung cancer patients
Eur. Respir. J., December 1, 2007; 30(6): 1186 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Gridelli, P. Maione, A. Illiano, F. V. Piantedosi, A. Favaretto, A. Bearz, S. F. Robbiati, V. Filipazzi, V. Lorusso, F. Carrozza, et al.
Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Non Small-Cell Lung Cancer: The MILES-2P Studies
J. Clin. Oncol., October 10, 2007; 25(29): 4663 - 4669.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. A. Socinski, R. Crowell, T. E. Hensing, C. J. Langer, R. Lilenbaum, A. B. Sandler, and D. Morris
Treatment of Non-small Cell Lung Cancer, Stage IV: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 277S - 289S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Gridelli, C. Langer, P. Maione, A. Rossi, and S. E. Schild
Lung Cancer in the Elderly
J. Clin. Oncol., May 10, 2007; 25(14): 1898 - 1907.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. M. Jackman, B. Y. Yeap, N. I. Lindeman, P. Fidias, M. S. Rabin, J. Temel, A. T. Skarin, M. Meyerson, A. J. Holmes, A. M. Borras, et al.
Phase II Clinical Trial of Chemotherapy-Naive Patients >= 70 Years of Age Treated With Erlotinib for Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 1, 2007; 25(7): 760 - 766.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Langer
Mind Your Elders: Therapeutic Implications of Epidermal Growth Factor Receptor Inhibition in Older Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 1, 2007; 25(7): 751 - 753.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Y. Seiwert, P. P. Connell, A. M. Mauer, P. C. Hoffman, C. M. George, L. Szeto, R. Salgia, K. E. Posther, B. Nguyen, D. J. Haraf, et al.
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung or Esophageal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 515 - 522.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. P. Fanucchi, F. V. Fossella, R. Belt, R. Natale, P. Fidias, D. P. Carbone, R. Govindan, L. E. Raez, F. Robert, M. Ribeiro, et al.
Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 1, 2006; 24(31): 5025 - 5033.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. A. Bunn Jr.
Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?
Clin. Cancer Res., October 15, 2006; 12(20): 5919 - 5920.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Giaccone, M. Gallegos Ruiz, T. Le Chevalier, N. Thatcher, E. Smit, J. A. Rodriguez, P. Janne, D. Oulid-Aissa, and J.-C. Soria
Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study.
Clin. Cancer Res., October 15, 2006; 12(20): 6049 - 6055.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. J. Weiss, C. Langer, R. Rosell, N. Hanna, F. Shepherd, L. H. Einhorn, B. Nguyen, S. Paul, P. McAndrews, P. A. Bunn Jr, et al.
Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., September 20, 2006; 24(27): 4405 - 4411.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. E. Vokes, M. C. Perry, H. L. Kindler, and M. R. Green
The cancer and leukemia group B respiratory committee.
Clin. Cancer Res., June 1, 2006; 12(11): 3581s - 3588s.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. A. Dooms, Y. N. Lievens, and J. F. Vansteenkiste
Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer
Eur. Respir. J., May 1, 2006; 27(5): 895 - 901.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Paccagnella, F. Oniga, A. Bearz, A. Favaretto, M. Clerici, F. Barbieri, A. Riccardi, A. Chella, U. Tirelli, G. Ceresoli, et al.
Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non-Small-Cell Lung Cancer: Results of a Phase II-III Study
J. Clin. Oncol., February 1, 2006; 24(4): 681 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. A. Socinski, A. Ivanova, K. Bakri, J. Wall, M. Q. Baggstrom, T. A. Hensing, A. Mears, M. Tynan, J. Beaumont, A. H. Peterman, et al.
A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
Ann. Onc., January 1, 2006; 17(1): 104 - 109.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. D. Thienelt, P. A. Bunn Jr, N. Hanna, A. Rosenberg, M. N. Needle, M. E. Long, D. L. Gustafson, and K. Kelly
Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non-Small-Cell Lung Cancer
J. Clin. Oncol., December 1, 2005; 23(34): 8786 - 8793.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. Gridelli and F. A. Shepherd
Chemotherapy for Elderly Patients With Non-Small Cell Lung Cancer: A Review of the Evidence
Chest, August 1, 2005; 128(2): 947 - 957.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online